Skip to main content

Table 2 Markers of ovarian reserve (serum hormones, ovarian volume, and antral follicular count) at baseline and after 6 months of therapy in the cyclophosphamide (CYC) and mycophenolate mofetil (MMF) groups

From: Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study

Parameter* CYC (n = 25) MMF (n = 25) Between-group p value (baseline) Between-group p value (6 months)
Baseline 6 months p value Baseline 6 months p value
LH (IU/ml) 5.8 ± 3.6 17.6 ± 38.4 0.13 9.4 ± 7.7 8.3 ± 5.6 0.55 0.065 0.55
FSH (IU/ml) 5.2 ± 3.4 25.1 ± 46.0 0.03 4.8 ± 1.8 6.1 ± 3.1 0.07 0.938 0.36
E2 (pg/ml) 80.2 ± 57.6 56.1 ± 52.3 0.13 89.6 ± 67.3 113.0 ± 73.3 0.25 0.749 < 0.001
AMH (ng/ml) 5.7 ± 6.7 1.2 ± 1.7 0.002 6.3 ± 3.9 5.8 ± 5.6 0.71 0.061 < 0.001
Inhibin B (pg/ml) 56.1 ± 21.9 16.5 ± 18.0 < 0.001 53.1 ± 24.7 82.9 ± 37.7 0.002 0.547 < 0.001
Ovarian volume (cm3) 29.3 ± 15.8 17.9 ± 13.7 0.005 25.7 ± 20.4 26.1 ± 11.1 0.92 0.49 0.02
Antral follicular count 6.4 ± 2.4 5.5 ± 4.2 0.32 6.7 ± 2.5 8.0 ± 3.0 0.07 0.74 0.02
  1. LH luteinizing hormone, FSH follicle-stimulating hormone, E2 estradiol, AMH anti-Mullerian hormone, CYC cyclophosphamide, MMF mycophenolate mofetil *Reported as mean ± SD